Targeting ineffective hematopoiesis in myelodysplastic syndromes COMMENT

被引：6
|
作者：
Patnaik, Mrinal M. [1 ]
Santini, Valeria [2 ]
机构：
[1] Mayo Clin, Div Hematol, Dept Internal Med, Rochester, MN 55902 USA
[2] Univ Florence, MDS Unit, Hematol, Florence, Italy
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2022年 / 97卷 / 02期
关键词：
EPOETIN-ALPHA; ROXADUSTAT FG-4592; LOW-RISK; LENALIDOMIDE; ANEMIA; PHASE-2; SAFETY; PLACEBO;
D O I：
10.1002/ajh.26416
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：171 / 173
页数：3
相关论文
共 50 条
  • [31] BESTATIN TREATMENT OF MYELODYSPLASTIC SYNDROMES (MDS) AND THE EFFECTS OF BESTATIN ON HEMATOPOIESIS IN MDS
    UZUKA, Y
    SAITO, Y
    ACTA ONCOLOGICA, 1990, 29 (06) : 803 - 807
  • [32] Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
    Steensma, David P.
    Bejar, Rafael
    Jaiswal, Siddhartha
    Lindsley, R. Coleman
    Sekeres, Mikkael A.
    Hasserjian, Robert P.
    Ebert, Benjamin L.
    BLOOD, 2015, 126 (01) : 9 - 16
  • [33] RECOVERY OF POLYCLONAL HEMATOPOIESIS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES FOLLOWING SUCCESSFUL CHEMOTHERAPY
    ITO, T
    OHASHI, H
    KAGAMI, Y
    ICHIKAWA, A
    SAITO, H
    HOTTA, T
    LEUKEMIA, 1994, 8 (05) : 839 - 843
  • [34] Protein kinase R (PKR) in the regulation of normal hematopoiesis and in myelodysplastic syndromes
    Sharma, Bhumika
    Verma, Amit
    Platanias, Leonidas C.
    CYTOKINE, 2010, 52 (1-2) : 85 - 85
  • [35] Extensive apoptosis of bone marrow cells as evaluated by the in situ end labelling (ISEL) technique may be the basis for ineffective hematopoiesis in patients with myelodysplastic syndromes.
    Parcharidou, A
    Raza, A
    Economopoulos, T
    Papageorgiou, E
    Anagnostou, D
    Papadaki, T
    Stamatopoulos, K
    Raptis, S
    BLOOD, 1995, 86 (10) : 3185 - 3185
  • [36] Treating myelodysplastic syndromes by nuclear transport inhibition Comment
    Sockel, Katja
    LANCET HAEMATOLOGY, 2020, 7 (08): : E552 - E553
  • [37] Ineffective hematopoiesis linked with a mitochondrial tRNA mutation (G3242A) in a patient with myelodysplastic syndrome
    Gattermann, N
    Wulfert, M
    Junge, B
    Germing, U
    Haas, R
    Hofhaus, G
    BLOOD, 2004, 103 (04) : 1499 - 1502
  • [38] Targeting TP53 Mutations in Myelodysplastic Syndromes
    Hunter, Anthony M.
    Sallman, David A.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2020, 34 (02) : 421 - +
  • [39] Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms
    Xie, Zhuoer
    Chen, Evan C. C.
    Mendez, Lourdes M.
    Komrokji, Rami
    Zeidan, Amer M.
    CANCER JOURNAL, 2023, 29 (03): : 130 - 137
  • [40] Microenvironment Profiling in Myelodysplastic Syndromes and Its Relationship to Clonal Hematopoiesis and Disease Progression
    Molero Yordi, Antonieta
    Tazon, Barbara
    Gallur, Laura
    Saumell, Silvia
    Jimenez, Tamara
    Ezponda, Teresa
    Julia Montoro, Maria
    Lopez Cadenas, Felix
    Altimiras, Lidia
    Sanchez Ruiz, Carla
    Alfonso, Ana
    Salamero, Olga
    Perez, Ana
    Peralta, Soraya
    Diez-Campelo, Maria
    Prosper, Felipe
    Bosch, Francesc
    Valcarcel, David
    BLOOD, 2021, 138
12345